View Older Stories View More Recent Stories

Sep 25, 2017 07:00AM Corbus Pharmaceuticals Announces Presentation of Three Abstracts at the 2017 North American Cystic Fibrosis Conference
Sep 20, 2017 08:00AM Corbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting
Sep 14, 2017 08:00AM Corbus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
Aug 31, 2017 08:05AM Corbus Pharmaceuticals to Host Fireside Chat on Dermatomyositis with Expert Physician and Researcher, Victoria Werth, MD
Aug 9, 2017 07:05AM Corbus Pharmaceuticals Reports 2017 Second Quarter Financial Results and Provides Business Update
Aug 7, 2017 07:05AM Corbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research
Jun 26, 2017 08:00AM Corbus Pharmaceuticals Announces Inclusion in Russell 3000(R) Index
Jun 15, 2017 07:08AM Corbus Pharma (CRBP) Announces Data from Phase 2 Study of Anabasum for the Treatment of Systemic Sclerosis
Jun 15, 2017 07:05AM Corbus Pharmaceuticals Presented Data from Phase 2 Study of Anabasum for the Treatment of Systemic Sclerosis at the EULAR 2017 Annual Meeting
Jun 8, 2017 09:10AM Corbus Pharmaceuticals to Present Data from Phase 2 Study of Anabasum at the European Cystic Fibrosis Society 2017 Conference
Jun 1, 2017 07:30AM Corbus Pharmaceuticals to Present at the 2017 Jefferies Global Healthcare Conference
May 11, 2017 08:14AM Corbus Pharma (CRBP) Says Last Subject Enrolled in Phase 2 Study of Anabasum
May 11, 2017 08:00AM Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
May 9, 2017 09:00AM Corbus Pharmaceuticals Reports 2017 First Quarter Financial Results and Provides Business Update
Apr 5, 2017 08:33AM Corbus Pharma (CRBP) Plans Single Phase 3 Study of Anabasum for Treatment of Systemic Sclerosis Following Guidance from FDA
Apr 5, 2017 08:30AM Corbus Pharmaceuticals to Commence Single Phase 3 Study of Anabasum for Treatment of Systemic Sclerosis Following Guidance Received from Successful End-of-Phase 2 Meeting with FDA
Mar 30, 2017 06:10AM Corbus Pharma (CRBP) Reports Positive Topline Ph2 Data for Multiple Doses of Anabasum (fka JBT-101 or Resunab) for the Treatment of Cystic Fibrosis
Mar 30, 2017 06:00AM Corbus Pharmaceuticals Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis
Mar 9, 2017 07:00AM Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update
Mar 8, 2017 08:00AM Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways
Mar 3, 2017 07:43AM Corbus Pharma (CRBP) Offers ~3.88M Shares at $7 to Develop JBT-101
Mar 3, 2017 07:30AM Corbus Pharmaceuticals Completes $27.2 Million Registered Direct Offering
Mar 1, 2017 07:30AM Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference
Feb 28, 2017 09:05AM Corbus Pharma (CRBP) to Sell 3.89M Shares at $7
Feb 28, 2017 09:00AM Corbus Pharmaceuticals Announces $27.2 Million Registered Direct Offering
Feb 23, 2017 08:26AM Corbus Pharma (CRBP) Says Preclinical Data Shows JBT-101 Reduces Inflammation in Alveolar Macrophages from CF Patients
Feb 23, 2017 08:05AM Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients
Feb 21, 2017 07:30AM Corbus Pharmaceuticals to Host Research and Development Day on March 13, 2017
Jan 17, 2017 07:33AM Corbus Pharma (CRBP) Receives UE Orphan Designation for JBT-101 for Treatment of Systemic Sclerosis
Jan 17, 2017 07:30AM Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union
Dec 29, 2016 07:32AM Corbus Pharma (CRBP) Completes Phase 2 CF Study of JBT-101; Expects to Report Results in Q1
Dec 29, 2016 07:30AM Corbus Pharmaceuticals Announces Completion of Phase 2 Study of JBT-101 (Resunab) for the Treatment of Cystic Fibrosis
Dec 5, 2016 10:00AM Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) to Ring The Nasdaq Stock Market Closing Bell
Dec 5, 2016 07:00AM Corbus Pharmaceuticals Announces NASDAQ Closing Bell Ceremony
Nov 29, 2016 07:30AM Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis
Nov 14, 2016 09:24AM Pre-Open Stock Movers 11/14: (CRBP) (HAR) (DGII) (MENT) Higher; (DVAX) (HEAR) (ACM) Lower (more...)
Nov 14, 2016 06:33AM Corbus Pharma (CRBP) Announces Topline Data from Resunab Phase 2 in SS Diffusion; Meaningful CRISS Score Noted
Nov 14, 2016 06:30AM Corbus Pharmaceuticals Reports Positive Topline Results Showing Clear Signal of Clinical Benefit with Resunab (JBT-101) in Phase 2 Study in Systemic Sclerosis
Nov 10, 2016 04:05PM Corbus Pharmaceuticals Reports 2016 Third Quarter Financial Results and Provides Business Update
Oct 18, 2016 07:05AM Corbus Pharma (CRBP) Receives EC Orphan Designation for Resunab as CF Treatment
Oct 18, 2016 07:00AM Corbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union
Oct 13, 2016 07:34AM Corbus Pharma (CRBP) Completes Resunab Phase 2 in Systemic Sclerosis
Oct 13, 2016 07:30AM Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis
Oct 5, 2016 09:20AM Pre-Open Stock Movers 10/05: (CPRX) (ACIA) (TWTR) Higher; (IMMU) (ULH) (CRM) Lower (more...)
Sep 28, 2016 07:30AM Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation
Sep 19, 2016 08:00AM Corbus Pharmaceuticals to Present at the Jefferies Cystic Fibrosis Summit
Sep 12, 2016 07:55AM Corbus Pharma (CRBP) Reports Last Subject Enrolled in Phase 2 Study of Resunab in CF
Sep 12, 2016 07:05AM Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis
Aug 15, 2016 07:30AM Corbus Pharmaceuticals Reports 2016 Second Quarter Financial Results and Provides Business Update
Jul 6, 2016 07:30AM Corbus Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016
View More Recent Stories View Older Stories